64 results about "Mucosal immunity" patented technology

The present invention concerns isolated human breast milk exosomes, and compositions thereof, and uses of said exosomes and compositions for promoting immunity and treating and / or preventing mucosal immunity and inflammation.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The invention discloses an influenza virus nano vaccine as well as a preparation method and application thereof. The invention relates to the field of biomedicine, and provides an influenza virus nano vaccine, which comprises nano particles and an STING agonist adsorbed on the surfaces of the nano particles, the nanoparticle comprises a polysaccharide antigen conjugate and a dendritic macromolecule, wherein the polysaccharide antigen conjugate is formed by coupling beta-glucan and influenza virus antigen protein, and the dendritic macromolecule and the polysaccharide antigen conjugate are adsorbed together. The immune response induced by the vaccine is higher than that of monomer immunogen protein without the adjuvant, body fluid, cell and mucosa immune response can be remarkably activated, lethal attack of an organism to H1N1 and H5N1 viruses can be effectively protected through nasal spray inoculation, and the nano vaccine can stimulate cross immune response and immune protection effect to different subtype influenza viruses.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The invention provides application of D-mannose in preparation of a product for improving intestinal mucosa immunity and / or intestinal flora homeostasis of weaned piglets, and particularly belongs to the technical field of weaned piglet breeding. The invention provides application of D-mannose in preparation of a product for improving intestinal mucosal immunity and / or intestinal flora homeostasis of weaned piglets. The D-mannose is derived from a natural plant, can stably and efficiently improve intestinal mucosa immunity and intestinal flora homeostasis of the weaned piglets, relieves diarrhea, and improves the growth performance of the weaned piglets at the same time. Specifically, D-mannose can improve the growth performance of weaned piglets, reduce the diarrhea rate, improve the intestinal structure, enhance the chemical barrier function of the intestinal tract, reduce the abundance of harmful bacteria in the intestinal tract and increase the content of short-chain fatty acid producing bacteria.

The invention belongs to the technical field of gene engineering, and particularly relates to recombinant lactobacillus for expressing clostridium perfringens multiple antigens of targeted dendritic cells as well as a construction method and application of the recombinant lactobacillus. The recombinant lactobacillus contains an expression vector for expressing a fusion gene; the fusion gene comprises sequences for coding and expressing a PgsA '-fimA fusion protein, a LysM-Fba fusion protein, an LP1261-NetB fusion protein, a phi54 targeting element and a Pas escape element; a sequence for coding the PgsA '-fimA fusion protein is shown as SEQ ID NO: 1, a sequence for coding the LysM-Fba fusion protein is shown as SEQ ID NO: 2, and a sequence for coding the LP1261-NetB fusion protein is shown as SEQ ID NO: 3. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunocompetence of organisms can be comprehensively enhanced, and the recombinant lactobacillus can be used for preparing oral vaccines for prevention and control of chicken necrotic enteritis.

The invention relates to the field of veterinary biological products, in particular to a porcine epidemic diarrhea virus attenuated strain and a vaccine and application thereof. The porcine epidemic diarrhea virus attenuated strain provided by the invention is obtained through in-vitro separation culture and continuous five rounds of plaque purification and screening technology, and has stable culture characteristics. Meanwhile, the virulence of the strain on newborn piglets and weaned piglets is remarkably reduced, and the virulence does not have the phenomenon of reversion after continuous passage for five times in a pig body. The strain has good immunogenicity, and mucosal immunity and systemic immune response of an organism can be activated at the same time by adopting an oral immunization mode. A neutralizing antibody of 1: 8-1: 16 can be detected in oral fluid and serum after the piglets are immunized for 14 days, and a large amount of sIgA is generated in milk after the pregnant sows are immunized, so that the piglets obtain effective passive immune protection.

The invention belongs to the technical field of genetically engineered bacteria, and particularly discloses an African swine fever oral vaccine saccharomyces cerevisiae engineered bacterium as well as a construction method and application thereof. A free plasmid system is adopted to transform saccharomyces cerevisiae, and an engineering strain for displaying ASFV p30 / p54 antigens is constructed. The matched plasmid system has the advantages of being simple and convenient to operate and short in construction period, construction and transformation of recombinant plasmids can be completed in a short time, and the research and development efficiency of vaccine candidate strains is remarkably improved. Meanwhile, the free plasmid can be stably inherited and copied in a yeast host, so that the expression stability of a target antigen in a passage process is guaranteed, and large-scale fermentation preparation is facilitated. After oral immunization, the saccharomyces cerevisiae engineering bacterium constructs a system-mucous membrane dual defense barrier in a tested animal pig body, not only induces high-level system IgG, but also induces remarkable sIgA mucous membrane immunity in intestinal tracts, and provides a new idea and technical reserve for research and development of ASFV subunit vaccines.

The application provides a lactic acid bacteria expressing an African swine fever virus fusion antigen and an application thereof. The lactic acid bacteria are integrated with a fusion gene, the fusion gene comprising a gene encoding an OprI protein and at least one gene selected from genes encoding a PP62 protein, an MGF505-3R protein, an EP364R protein, a K145R protein and a DP96R protein, and a starting strain of the lactic acid bacteria is Lactobacillus plantarum. Using the lactic acid bacteria to immunize animals can induce mucosal immunity, cellular immunity and humoral immunity responses, and comprehensively enhance the immune capacity of the body, and the lactic acid bacteria can be used for preparing an oral vaccine for the prevention and control of African swine fever.

The invention belongs to the technical field of health-care products, and discloses an oligosaccharide selenium ganoderma lucidum capsule for enhancing immunity and inhibiting tumors and a preparation method, and the content of the capsule is prepared from the following raw materials in parts by mass: 150-160 parts of collagen, 80-85 parts of chitosan oligosaccharide, 110-130 parts of ganoderma lucidum extract, 45-55 parts of selenium-enriched yeast, 50-80 parts of maltodextrin and 7-10 parts of magnesium stearate. The skin barrier can be improved, intercellular communication can be promoted and local immune response can be stimulated through low-molecular peptide of collagen, intestinal flora balance can be adjusted through chitosan oligosaccharide, probiotic growth can be promoted, mucous membrane immunity can be further improved, and finally immune cells can be effectively activated through polysaccharide and triterpenoids in the ganoderma lucidum extract, so that the immunity of a human body is improved. The activity of macrophages and natural killer cells is enhanced, and the multi-target and multi-path immune regulation effect can effectively enhance the defense of the body to pathogenic microorganisms.

The invention discloses a composition for preventing and treating oral diseases or conditions, a preparation method and application thereof. The external vesicles based on oral pathogenic bacteria are rich in nano-scale vesicles of immune activation and defense factors aiming at periodontitis, and after the external vesicles enter a body through oral mucosa administration, the external vesicles are passively targeted into lymph nodes related to the oral mucosa to induce mucosa immune specific antibody expression, so that the immune defense capacity to the pathogenic bacteria is improved. Preferably, a calcium phosphate shell is coated outside the oral bacterial outer vesicle, and the calcium phosphate shell can only be dissolved under an acidic condition, so that the engineered vesicle can be degraded after targeting to lymph nodes and being phagocytosed into dendritic cell lysosome, and the inflammatory reaction of a drug delivery area is avoided. The administration form of the sublingual disintegrating tablet can improve the bioavailability of the vaccine while local mucosal administration activates mucosal immunity, and the convenient administration form is also beneficial to the promotion and popularization of the periodontitis vaccine in clinical chair-side diagnosis and treatment or grassroots communities.

The invention relates to the technical field of medicines, and provides a construction method and application of a smog-induced IgA nephropathy mouse model. An IgAN model based on PM2.5 continuous exposure induction is constructed, the influence of long-term environmental particulate matter stimulation on respiratory mucosal immunity can be simulated, and a key chain of mucosal immune activate-Gd-IgA1 overexpression-immune complex formation in human IgAN is effectively simulated, so that the correlation between kidney phenotypic change and mucosal immune activation is observed, and the accuracy and the sensitivity of the kidney phenotypic change are improved. And evidence is provided for direct association of the mucous membrane system and the renal injury. The model better conforms to the human pathogenesis background, the phenotype is stable, the operation is controllable, and conversion or popularization is facilitated.

The invention relates to the technical field of medicines, in particular to a zinc ion polypeptide compound immunologic adjuvant as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing polypeptide, a PBS buffer solution, new coronavirus S protein, a CpG ODN immune activator and zinc ions, and standing to obtain the zinc ion polypeptide compound immunologic adjuvant. A dual-adjuvant system mixed with CpG ODN shows excellent performance in activation of lung tissue immunity, and in the cellular immunity level, the response intensity of CD4 + T and CD8 + T cells is enhanced, and formation of related tissue resident memory T cell phenotypes is promoted; on the humoral immunity level, a Gel (Zn < 2 + >) and CpG ODN dual-adjuvant system obviously stimulates the increase of the number of B cells and the activation, and can effectively stimulate the secretion of a main antibody sIgA for mucosal immunity. On the whole, the dual adjuvants realize the synergistic enhancement of T cell (containing TRM) and B cell immunity.

Provided are a composition for preventing and treating an oral disease or condition, a preparation method therefor, and the use thereof. The composition comprises extracellular vesicles derived from oral pathogenic bacteria. The extracellular vesicles are nanoscale vesicles rich in immune activation and defensive factors against pathogenic bacterial infection. Upon administration via the oral mucosa into a body, the vesicles are passively aimed at lymph nodes associated with the oral mucosa to induce the expression of a mucosal immunity-specific antibody, thereby enhancing immune defense against pathogenic bacteria. The extracellular vesicles of oral pathogenic bacteria are coated with a calcium phosphate shell, and the shell is soluble only under acidic conditions and degrades only after the extracellular vesicles are aimed at the lymph nodes and are phagocytosed into lysosomes of dendritic cells, thereby avoiding inflammatory reactions in an administration area. By using a sublingual disintegrating tablet as the form of administration, the bioavailability of a vaccine can be enhanced while achieving the local administration at the mucosa and activating mucosal immunity. Moreover, the composition is convenient to administer, which is conducive to the diagnosis and treatment of oral bacterial infectious diseases.

The application specifically discloses a kind of nanovaccine for thrombosis prevention and its preparation method and application, it is related to thrombotic disease, especially related to the nanovaccine for treating thrombotic disease.The nanovaccine provided by the application has good immunogenicity without macromolecular heterologous protein carrier such as KLH;The process simplicity and repeatability are improved by reducing complex chemical coupling and purification steps;The dependence on traditional high-stimulating immune adjuvant is reduced, and the biological safety is improved;The stability of antigen in gastrointestinal environment is significantly improved;Active targeting delivery of M cells and dendritic cells is realized;Dendritic cell maturation and antigen presentation are promoted, and mucosal immunity and systemic immunity level are improved;The advantages such as effectively inhibiting thrombosis are realized, and a new type of oral antithrombotic vaccine system with high compliance suitable for long-term thrombosis prevention is constructed.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant lactobacillus plantarum for preventing and controlling chicken necrotic enteritis as well as a preparation method and application of the recombinant lactobacillus plantarum. The invention provides an oral vaccine vector capable of co-expressing various key virulence factor antigens (FimB, NetB, CnaA and FBA) of clostridium perfringens, and by fusing dendritic cell (DC) targeting molecules (nano antibody Phi74), the efficiency of recognizing and taking in the vaccine vector by full-time antigen presenting cells is remarkably improved, so that the immunogenicity is enhanced. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunity of organisms is comprehensively enhanced, and a safe and efficient oral immunization scheme suitable for large-scale breeding is established for treating chicken necrotic enteritis.

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

The application discloses a mucosal immunity enhanced recombinant lactobacillus expressing PEDV S1 protein and a construction method and application thereof. The mucosal immunity enhanced recombinant lactobacillus contains a recombinant lactic acid bacteria expression vector expressing the PEDV S1 protein, wherein the PEDV S1 protein is fused with an M cell targeting peptide (Col) and a dendritic cell targeting peptide (6aa) at an amino acid end, and is fused with a mucosal immunity adjuvant (LTB) at a carboxyl end; and the connection sequence of each part is Col-6aa-S1-LTB. The mucosal immunity enhanced recombinant lactobacillus constructed by the application significantly improves the mucosal immunity response efficiency (including intestinal mucus SIgA and serum IgG levels) of the PEDV S1 antigen through the synergistic effect of the targeting peptide (DC / MC targeting peptide) and the adjuvant (LTB), and can significantly induce humoral immunity, cellular immunity and mucosal immunity response of pregnant animals and produce maternal antibodies, improves the intestinal SIgA level of newborn animals, and provides an effective technical means for the prevention and treatment of PED.

The invention discloses a composite adjuvant suitable for mucosal immunity. The mucosal composite adjuvant comprises the following components in percentage by mass: 0.25-5% of sodium carboxymethyl cellulose, 0.5-3% of microcrystalline cellulose, polyinosinic-polycytidylic acid with the final concentration of 0.5-5 mg / ml and cyclic dinucleotide with the final concentration of 100-300 mu g / ml. The composite adjuvant disclosed by the invention is combined with a recombinant novel coronavirus antigen protein or influenza virus split vaccine antigen protein, through local mucous membrane administration, a good mucous membrane immunological effect is generated locally on the mucous membrane, a high-level neutralizing antibody of the whole body can be stimulated to be generated, and meanwhile, the composite adjuvant has a good cellular immune effect and can be used for preparing the vaccine for treating the influenza virus. And the method has a good and wide application prospect in the development of vaccines or medicines for local administration through mucosa.

The invention provides recombinant lactobacillus plantarum for expressing porcine epidemic diarrhea virus S1 protein as well as a preparation method and application of the recombinant lactobacillus plantarum, and belongs to the technical field of preparation of porcine epidemic diarrhea virus vaccines. The recombinant lactobacillus plantarum provided by the invention contains a recombinant vector for expressing a PEDV tS1 fusion gene, and the PEDV tS1 fusion gene comprises a PEDV tS1 structural domain, an endogenous signal peptide 1320 and a dendritic cell targeting peptide DCpep. After the recombinant lactobacillus plantarum provided by the invention is used as a mucosal vaccine through nasal dripping, not only can a codon be prevented from being repeatedly optimized, but also strong cross-species immune response can be induced, pathogen specificity sIgA can be generated, mucosal immunity can be effectively activated, and the induced antibody has the activity of neutralizing PEDV (porcine epidemic diarrhea virus). The recombinant lactobacillus plantarum provided by the invention has a treatment effect.

The application discloses an immunological composition containing a fatty acid modified SpyCatcher protein and a preparation method thereof, and belongs to the field of biological medicines; wherein the SpyCatcher protein (LipoSC) can self-polymerize into nanoparticles, and covalent connection with an antigen containing a SpyTag polypeptide through an isopeptide bond can improve the immunogenicity of the loaded antigen; taking the receptor binding domain (RBD) of the coronavirus spike protein (S protein) as an example, the immunological composition containing the fatty acid modified SpyCatcher protein and the coronavirus RBD antigen disclosed by the application can induce a strong RBD specific immune response, and in particular, as a mucosal subunit vaccine, can induce antigen specific mucosal immunity and humoral immunity. The application further provides a method for realizing the fatty acid modification of the SpyCatcher protein in Escherichia coli, and a method for preparing various immunological compositions by using the fatty acid modified protein.

The invention relates to the technical field of polysaccharide liposomes, in particular to a cichorium intybus sugar lipidosome multifunctional vaccine diluent, a preparation method and application of the cichorium intybus sugar lipidosome multifunctional vaccine diluent. Cichorium intybus polysaccharide is encapsulated by lipidosome, and the obtained cichorium intybus polysaccharide lipidosome is diluted through a phosphate buffer solution to be used for preparing newcastle disease vaccines. The mucosal immunity of the chicken can be improved, the immune function of the body can be enhanced, and the antibody titer is improved by cooperating with the vaccine; meanwhile, the decline rate of antibody titer can be delayed, and the action time of vaccine immunocompetence can be prolonged.

The invention provides an HXT3-VP8 fusion protein, a yeast extracellular vesicle loaded with the HXT3-VP8 fusion protein, a vaccine and application, and relates to the technical field of biology. The HXT3-VP8 fusion protein sequentially comprises an HXT3 fragment and a VP8 fragment from the N fragment to the C terminal, the yeast extracellular vesicle loads the HXT3-VP8 fusion protein, and the VP8 fragment is located in the extracellular vesicle. When the yeast extracellular vesicles are used for immunizing animals, safety is achieved, and the response of body humoral immunity and mucosal immunity can be stimulated.

A preparation method for a multifunctional biomimetic delivery platform efficiently crossing mucosal barriers and inducing mucosal immune enhancement and use thereof. The present invention relates to the technical field of biopharmaceuticals. On the basis of a biodegradable PLGA copolymer and a mixed lipid component, mucosal delivery carrier particles capable of simultaneously loading multiple antigens and immunostimulatory components are prepared by means of a double emulsion method, a rotary evaporation coating method, and an ultrasonic method. The PLGA nanoparticles are loading cores. The outer mixed lipid coating can fulfil the functions of mucus penetration, cell uptake, and thus immune activation.

The invention belongs to the technical field of biology, relates to a haemophilus parasuis subunit vaccine as well as a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises a recombinant P3 protein and a recombinant P5 protein, the recombinant P3 protein is coded by a sequence shown in SEQ ID No.1, the recombinant P5 protein is coded by a sequence shown in SEQ ID No.2, and the recombinant P3 protein is coded by a sequence shown in SEQ ID No.2. The vaccine immunization can induce effective respiratory mucosa immune response, meanwhile, humoral immune and cellular immune response are remarkably induced, the safety is high, live pathogens are not involved in the vaccine preparation process, no adverse reaction is generated after immunization, and mucosa immunity can be activated when the vaccine immunizes a body; the required antigen content is obviously lower than that of the existing vaccine, the mucosal immunity is enhanced and the immune duration is prolonged by screening adjuvants, and a good immune protection effect can be provided.

The invention belongs to the technical field of biology, particularly relates to a haemophilus parasuis disease mucosal immune vaccine, a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises one or more of a recombinant P2 protein, a recombinant P3 protein and a recombinant P6 protein, sequences for coding the haemophilus parasuis antigen combination are shown as SEQ ID No.1-3 respectively, and the haemophilus parasuis antigen combination comprises one or more of the recombinant P2 protein, the recombinant P3 protein and the recombinant P6 protein. The haemophilus parasuis antigen combination is prepared into a haemophilus parasuis disease mucosal immune vaccine, the haemophilus parasuis disease mucosal immune vaccine is safe and free of biological safety risks, an immune body can activate comprehensive immune reactions including humoral immunity and cellular immunity, and more importantly, remarkable mucosal immunity can be induced; the antigen has good immunogenicity and good conservative property, and can provide broader spectrum protection. By means of mucous membrane immunization, conventional injection immune stress reaction is reduced, and side reaction is small. And the problem that pathogenic bacteria are not thoroughly inactivated possibly in the production of the inactivated vaccine is also solved, the pathogenic bacteria diffusion and pollution risks are reduced, and the method has a wide application prospect.

The application relates to the field of biological medicine, and particularly discloses an oral double-targeting brucellosis nano-vaccine CS-CKS9-MEV-DCpep-NPs construction method and application thereof, the nano-vaccine comprises chitosan nanoparticles and a double-targeting peptide vaccine CKS9-MEV-DCpep encapsulated in the chitosan nanoparticles, the double-targeting peptide vaccine CKS9-MEV-DCpep comprises, from N-terminal to C-terminal, an M cell targeting peptide CKS9, a polyepitope vaccine MEV and a DC targeting peptide DCpep; the application also provides a method for constructing the nano-vaccine and application thereof. The application successfully constructs the oral CS-CKS9-MEV-DCpep-NPs nano-vaccine through a systematic strategy of integrating 'bioinformatics precise screening, double-targeting molecular modification and excellent carrier delivery', the nano-vaccine has double-targeting functions of mucosal immunity and cellular immunity, can effectively induce mucosal immunity, cellular immunity and humoral immunity, and exhibits excellent protection efficacy in acute and chronic infection models, thereby providing a new effective solution for brucellosis prevention and control.

The invention belongs to the technical field of bioengineering, and particularly relates to a recombinant adenovirus vector for expressing a PEDV-TGEV receptor binding domain as well as a preparation method and application of the recombinant adenovirus vector. Human type 5 defective adenovirus is used as an expression vector, RBD gene segments of PEDV and TGEV are optimized at the same time, a vector capable of efficiently expressing TGEV-PEDV receptor binding domain antigen protein is constructed, and the vector has good immunogenicity and can induce mucosal immunity, cellular immunity and humoral immunity response, so that the immunity is remarkably improved, and the TGEV-PEDV receptor binding domain antigen protein can be used for preparing the TGEV-PEDV receptor binding domain antigen protein. The method has a wide application prospect in the field of immunotherapy of swine transmissible gastroenteritis and porcine epidemic diarrhea.